Vox

ONE-CLICK AUTOMATED 3D TREATMENT PLANNING FOR RADIOPHARMACEUTICAL THERAPY

DEVELOPING A SUSTAINABLE ELECTRONIC REPORTING & MONITORING SYSTEM FOR HIV/AIDS

INTEGRATING HIV/AIDS PROGRAM ELECTRONIC MONITORING AND REPORTING SYSTEM IN THE RE

NANOPARTICLE-BASED SENSITIZER FOR RADIATION THERAPY OF GLIOBLASTOMA

NEW SBIR PHASE I 2009: HIGH-DYNAMIC-RANGE, RAD-HARD, TIME-RESOLVED, CORRELATED X-RAY PHOTON DETECTOR; PI - GEORGE WILLIAMS

TAS::89 0222::TAS NEW PHASE I SBIR; TITLE: HIGH SPEED GERMANIUM X-RAY PHOTON COUNTING DETECTOR ARRAY; PI: ANDREW HUNTINGTON

EXHALED BREATH DRUG DETECTION USING DIFFERENTIAL MOBILITY SPECTROMETRY

TORCH RECON: AN INNOVATIVE RECONSTRUCTION SOFTWARE FOR INCREASED THROUGHPUT AND IMPROVED LOW-COUNT QUANTITATIVE SPECT IMAGING - PROJECT SUMMARY/ABSTRACT SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) IMAGING PLAYS A PIVOTAL ROLE IN RADIOPHARMACEUTICAL THERAPY (RPT), ALLOWING CLINICIANS TO PERSONALIZE PRESCRIPTIONS AND ASSESS TREATMENT RESPONSE. HOWEVER, TRADITIONAL SPECT RECONSTRUCTION METHODS OFTEN ENCOUNTER CHALLENGES RELATED TO NOISE, ARTIFACTS, AND LENGTHY PROCESSING TIMES. IN IMAGING, ACCURATE CORRECTION OF SCATTERING EFFECTS AND ENHANCEMENT OF SIGNAL-TO-NOISE RATIO (SNR) ARE CRITICAL FOR ACHIEVING QUANTITIVELY ACCURATE IMAGES REQUIRED FOR DOSIMETRY GUIDANCE OF RPT AND TREATMENT RESPONSE ASSESSMENT. TORCH RECON IS A CUTTING-EDGE SOFTWARE THAT HARNESSES THE SYNERGISTIC POWER OF MONTE CARLO SIMULATION AND DEEP LEARNING TECHNIQUES TO ADDRESS THE LIMITATIONS OF CONVENTIONAL RECONSTRUCTION METHODS. MONTE CARLO SIMULATION ACCURATELY MODELS PHOTON INTERACTIONS WITHIN TISSUES, LEADING TO IMPROVED ACCURACY AND RESOLUTION IN THE RECONSTRUCTED IMAGES. COMPLEMENTING THIS, DEEP LEARNING ALGORITHMS ARE EMPLOYED TO ENHANCE IMAGE QUALITY, REDUCE NOISE, AND SUPPRESS ARTIFACTS. THESE ALGORITHMS LEVERAGE LARGE DATASETS TO LEARN INTRICATE PATTERNS AND RELATIONSHIPS, RESULTING IN SHARPER, MORE INFORMATIVE SPECT IMAGES. TORCH RECON REPRESENTS THE FUSION OF MONTE CARLO SIMULATION AND DEEP LEARNING, ENABLING A DYNAMIC AND ADAPTIVE RECONSTRUCTION PROCESS WHICH HAS THE POTENTIAL TO NOT ONLY IMPROVE QUANTITATIVE SPECT BUT ALSO SNR WHICH IS ESPECIALLY IMPORTANT FOR SCENARIOS WITH LOW COUNTING STATISTICS, E.G., ALPHA EMITTERS. AS PART OF A PREVIOUS PHASE I CONTRACT, WE INCORPORATED A SPECT RECONSTRUCTION ALGORITHM WITH A GPU-ACCELERATED MONTE CARLO-BASED SCATTER ESTIMATOR INTO THE GPU-BASED TORCH SOFTWARE SYSTEM FOR RPT DOSIMETRY. IN THIS PHASE II PROPOSAL, WE WILL (1) IMPLEMENT AI DENOISING TECHNIQUES INTO TORCH RECON, (2) ASSESS ACCURACY AND PERFORMANCE OF THE RECONSTRUCTION SOFTWARE USING PHANTOMS, AND (3) VALIDATE CLINICAL USABILITY AND EFFECTIVENESS THROUGH A PROSPECTIVE CLINICAL TRIAL. BY COMPLETING THE MILESTONES OF THIS PHASE II PROPOSAL, TORCH RECON WILL BE READY FOR 510(K) CLEARANCE AND COMMERCIALIZATION.

TAS::89 0222::TAS NEW PHASE I SBIR; TITLE: SOI CMOS WAFER SCALE IMAGER PLATFORM; PI: ADAM LEE

TAS::89 0222::TAS NEW PHASE I 2010 SBIR; TITLE: DEVELOPMENT OF COMMERCIAL FOUNDRY SOURCE FOR SCIENCE-GRADE CHARGED PARTICLE IMAGERS; PI: GEORGE WILL

TAS::89 0222::TAS SOLUTION-PROCESSED, LARGE AREA, PIXELATED DIRECT-DETECTION RAIATION DETECTORS

TAS::89 0222::TAS NEW PHASE I SBIR; TITLE: LOW COST, RECONFIGURABLE, MULTI-CHANNEL PULSE PROCESSING PLATFORM; PI: ANDREW HUNTINGTON

RETINAL IMAGE ANALYSIS SOFTWARE FOR NEURODEGENERATIVE DISEASE RESEARCH - OPHTHALMIC IMAGING IS OF CRITICAL IMPORTANCE TO OCULAR DISEASE MANAGEMENT AND, INCREASINGLY, AS A WINDOW TO NEURODEGENERATIVE AND SYSTEMIC DISEASES. OPTICAL COHERENCE TOMOGRAPHY (OCT) IS ITS MOST IMPORTANT MODALITY, BUT ALSO ITS MOST PROBLEMATIC IN TERMS OF INTEROPERABILITY, STORAGE AND UNIFIED ANALYSES. MUCH OF THIS IS TO DO WITH INCOMPATIBLE INSTRUMENTS AND DATA FORMATS. RAPID ADVANCES IN RADIOLOGY RESULTED FROM THE DICOM STANDARDIZATION OF IMAGE DATA, FACILITATING MORE COLLABORATIVE WORK, BETTER DATA INSIGHT, DEVICE INDEPENDENCE AND INNOVATIVE DEVELOPMENTS THAT TODAY HAVE SPAWNED MULTIPLE INDEPENDENT VENDORS OFFERING PROCESSING AND ARCHIVAL SOLUTIONS. FOR OCT, NO SUCH SOLUTION EXISTS AND, AS A DIRECT RESULT, DESPITE BEING THE STANDARD OF CARE, THE CLINICAL DATA REMAINS UNDER-UTILIZED AND THE RESEARCH FRAGMENTED. OPEN FORMATS REDUCE OVERALL COSTS AND CAN ULTIMATELY LEAD TO BETTER PATIENT OUTCOMES. THIS PROJECT WILL ESTABLISH THE FIRST, COMMERCIAL GRADE, CLOUD-BASED, TRULY VENDOR NEUTRAL, DICOM COMPLIANT, IMAGE AND INFORMATION STORAGE AND PROCESSING PLATFORM FOR OPHTHALMIC OCT. THE PROPOSED SYSTEM WILL BRING THE FUNCTIONALITY, INTEROPERABILITY, AND INNOVATION OF RADIOLOGY TO OPHTHALMOLOGY. THE PROJECT HAS THE FOLLOWING CLEAR AND ACHIEVABLE MILESTONES: 1) DEVELOP NEBULA, A CLOUD-BASED, DICOM-COMPLIANT, IMAGE STORAGE AND ARCHIVE PLATFORM. THIS WILL BE BUILT WITH SECURITY AS THE PRIMARY CONSIDERATION AND WILL NATIVELY SUPPORT PATIENT MANAGEMENT SYSTEMS. 2) ADD A WEB-BASED ANALYSIS FRONT-END TO NEBULA OPTIMIZED FOR CLINICAL OPHTHALMIC WORKFLOWS. 3) BUILD ON OUR PHASE I AWARD, AND IMPLEMENT, VALIDATE AND RELEASE AI-BASED AMD PROGNOSTICS, OCT-ANGIOGRAPHY ANALYTICS AND RETINAL FLUID QUANTIFICATION SOFTWARE. 4) APPLY FOR REGULATORY APPROVAL FOR BOTH NEBULA’S PICTURE ARCHIVING AND COMMUNICATIONS (PACS) FOR OPHTHALMOLOGY AND THE FLUID QUANTIFICATION MODULE. THIS WILL ALLOW FOR CLINICAL USE OF THE SYSTEM AND SERVE AS A PLATFORM FOR A WIDE VARIETY OF OPHTHALMIC AND NEUROLOGIC RESEARCH. WE HAVE RECEIVED SIGNIFICANT INTEREST IN THE PROPOSED WORK FROM RESEARCHERS, OPHTHALMOLOGISTS, AND OPTOMETRISTS. AND, TOWARD THESE ENDS, WE HAVE ASSEMBLED A TEAM OF EXPERTS TO MANAGE, IMPLEMENT, VALIDATE, AND RELEASE THIS SOFTWARE. THAT IS, TO ACHIEVE ALL THE AIMS PRESENTED.

LONG TERM RADIATION TREATMENT PLANNING IN BRAIN TUMORS IN THE PEDIATRIC POPULATION - PROJECT SUMMARY AND ABSTRACT RADIATION THERAPY (RT) HAS A PROVEN RECORD OF EFFICACY IN TREATING MANY FORMS OF PEDIATRIC BRAIN TUMORS. HOWEVER, IT IS ASSOCIATED WITH LONG-TERM SIDE EFFECTS DUE TO DAMAGE TO SURROUNDING HEALTHY TISSUE. THIS IS ESPECIALLY IMPORTANT IN THE PEDIATRIC DEVELOPING BRAIN, WHERE LONG-TERM DEFICITS CAN BE SEEN IN COGNITIVE DEVELOPMENT. TO MITIGATE THESE DEFICITS, THERE HAS BEEN A SHIFT FROM WHOLE BRAIN IRRADIATION TO MORE TARGETED TREATMENT BY USING DOSE PAINTING INTENSITY MODULATED RADIATION THERAPY. HOWEVER, TO USE THESE TECHNIQUES, MORE INFORMATION IS NEEDED ABOUT HOW GIVING RADIATION TO NORMAL BRAIN STRUCTURES, CALLED ORGANS-AT-RISK (OARS) AFFECTS OUTCOMES, BOTH IN TERMS OF BRAIN ANATOMY AND FUNCTION. VOXEL HEALTHCARE LLC (VH) IS THE DEVELOPER OF CLICKBRAIN – AN AUTOMATIC PEDIATRIC MR BRAIN SEGMENTATION TOOL THAT USES CLOUD-BASED DEEP LEARNING (GOOGLE TENSORFLOW) TECHNOLOGY FOR RADIOLOGY CLINICAL DECISION SUPPORT. SINCE THE INCEPTION OF THIS SOFTWARE, WE EXTENDED CLICKBRAIN TO CLICKBRAIN RT – A SYSTEM THAT WILL COMBINE CLICKBRAIN’S PRETREATMENT BRAIN STRUCTURE SEGMENTATION OUTPUTS WITH RADIATION PLANNING COMPUTED TOMOGRAPHY (CTS) AND/OR MAGNETIC RESONANCE (MRS) IMAGING TO CALCULATE DOSE TO OARS. CLICKBRAIN RT ALSO SEGMENTS LONGITUDINAL MRIS TO TRACK OUTCOMES VIA VOLUMETRIC CHANGES. IN PREVIOUS PROJECTS, WE CORRELATED INPUT PARAMETERS SUCH AS OAR DOSING, DEMOGRAPHICS, TUMOR TYPE AND GRADE, OAR AND TUMOR VOLUMETRIC MEASUREMENTS TO OAR VOLUMETRIC OUTCOMES, USING A DATABASE OF BRAIN MRIS FROM GERM CELL TUMOR PATIENTS. HERE IN AIM 1A, WE WILL MODIFY OUR PREDICTION USING A HYBRID DEEP LEARNING AND MACHINE LEARNING METHOD FOR THE PREDICTION OF TREATMENT OUTCOMES FOR OAR. WE WILL ALSO BE IMPROVING OUR AUTOSEGMENT ALGORITHMS. THE TUMOR IMAGES EXTRACTED FROM MRI AND CT IMAGES WILL BE CONCATENATED WITH THE PATIENT SPECIFIC DEMOGRAPHIC INFORMATION (AGE AND GENDER) FOR THE TRAINING OF A HYBRID NEURAL NETWORK ARCHITECTURE. IMAGING FEATURES WILL BE SENT TO AN AUTOENCODER CONVOLUTIONAL NEURAL NETWORK (CNN), WHILE THE DEMOGRAPHIC INFORMATION WILL BE SENT TO A DENSELY CONNECTED MULTI-LAYER PERCEPTRON (MLP) NETWORK. AFTER INDIVIDUAL FEATURE EXTRACTION AND RESHAPING, THEY WILL BE CONCATENATED AND SENT TO A MLP MODEL FOR TREATMENT LATE COGNITIVE EFFECTS PREDICTION. MISSING DATA POINTS WILL BE SYNTHESIZED USING A MODIFIED PIX2PIX GENERATIVE ADVERSARIAL NETWORK (GAN) METHOD. 3. IN AIM 1B, WE WILL BUILD ON OUR CURRENT INTERFACE PROTOTYPE, WHICH USES CLINICAL AND DEMOGRAPHIC VARIABLES (AGE, CHEMOTHERAPY DOSE, TUMOR TYPE, GRADE AND LOCATION) AND BASELINE IMAGING AS INPUT AND OUTPUTS PREDICTED OUTCOMES FOR OARS. WE WILL UPGRADE THE INTERFACE TO PROVIDE FULL FUNCTIONALITY AND COMPATIBILITY WITH EXISTING COMMERCIAL SOFTWARE FOR EASE OF PORTING FILES BETWEEN SYSTEMS. OUR EXTENDED VALIDATION IN AIM 2 WILL FOCUS ON AN EXISTING LARGE DATABASE FROM A BROAD RANGE OF BRAIN TUMOR PATIENTS ACQUIRED AS PART OF STANDARD-OF-CARE AND PREVIOUS STUDIES AT CHILDREN’S HOSPITAL LOS ANGELES. OUR LONG-TERM GOAL FOR CLICKBRAIN RT IS TO TRAIN THE MACHINE LEARNING ALGORITHM TO PROVIDE OPTIMIZED RECOMMENDED OAR DOSAGE RANGES BASED ON PATIENT HISTORY AND TUMOR INFORMATION. OUR SOFTWARE WILL ALLOW RADIATION ONCOLOGISTS TO OPTIMIZE TREATMENT AND VASTLY IMPROVE LONG-TERM QUALITY OF LIFE IN PEDIATRIC BRAIN TUMOR SURVIVORS.

DEVELOPING AND SCALING AN INTERACTIVE TEXT MESSAGING TOOL TO HELP PREGNANTSMOKER

PANCREATIC DUCTAL ADENOCARCINOMA TARGETED ULTRASOUND CONTRAST AGENT DEVELOPMENT

SBIR-PHASE I NEW; WAFER-SCALE GEIGER-MODE SILICON PHOTOMULTIPLIER ARRAYS FABRICATED USING DOMESTIC CMOS FAB; VINIT DHULLA

ETA: EXTENSIBLE TOOLS FOR ANALYTICS IN PUBLIC SAFETY

GEO-REFERENCED, UAV-BASED 3D SURVEYING SYSTEM FOR PRECISION CONSTRUCTION

DIGITAL SILICON PHOTOMULTIPLIER READOUT CIRCUIT

LARGE-FORMAT, HIGH-THROUGHPUT PHOTON-COUNTING IMAGER

LOW SWAP LIDAR INSTRUMENT FOR ARCTIC ICE SHEET MASS BALANCE MONITORING

MICRON-SCALE DIRECT-DETECTION X-RAY DETECTORS

RAD-HARD DUAL-THRESHOLD HIGH COUNT RATE SILICON PIXEL ARRAY DETECTOR

LIQUID BIOPSY IN GLIOBLASTOMA TREATED WITH CHEMORADIATION AND AN OXYGEN THERAPEUTIC - HYPOTHESIS AND SPECIFIC AIMS OUTCOMES FOR PATIENTS WITH GLIOBLASTOMA (GBM), THE MOST AGGRESSIVE MALIGNANT BRAIN TUMOR IN ADULTS, ARE DRIVEN BY THE GENETIC UNDERPINNING OF THE TUMOR, SUCH AS METHYLATION STATUS OF METHYL GUANINE METHYLTRANSFERASE (MGMT) GENE PROMOTER AND EXPRESSION OF TUMOR HYPOXIA GENES. STANDARD TREATMENT FOR GBM PATIENTS IS SURGERY FOLLOWED BY CHEMORADIATION WITH ROUTINE SERIAL MRI TO ASSESS TREATMENT RESPONSE. AFTER CHEMORADIATION, MR IMAGING MAY EXHIBIT INCREASED ENHANCEMENT THAT COULD REPRESENT TUMOR IN 30% OR MORE OF CASES, THE PHENOMENON OF PSEUDOPROGRESSION (PSP) FROM TREATMENT. IT IS CHALLENGING TO DISTINGUISH BETWEEN TRUE PROGRESSION AND PSP, SO PATIENTS AND PROVIDERS NEED OTHER MEANS TO EVALUATE THE DISEASE TRAJECTORY. LIQUID BIOPSY IS A NON-INVASIVE APPROACH TO EVALUATE DISEASE TRAJECTORY THROUGH TUMOR GENOTYPE AND GENE EXPRESSION. GBM IS A HYPOXIC TUMOR; TUMOR HYPOXIA IS KNOWN TO CURTAIL RESPONSE TO CHEMORADIATION. DODECAFLUOROPENTANE EMULSION (DDFPE) WAS TESTED IN A PHASE IIA TRIAL IN ASSOCIATION WITH CHEMORADIATION TO TREAT GBM. DDFPE WAS WELL TOLERATED, SHOWED REVERSAL OF TUMOR HYPOXIA, AND DEMONSTRATED IMPROVED PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS). ENROLLMENT IS UNDERWAY IN A PHASE IIB TRIAL TESTING DDFPE AS AN OXYGEN THERAPEUTIC (RADIOSENSITIZER) IN ASSOCIATION WITH CHEMORADIATION TREATMENT IN GBM PATIENTS. PRIOR WORK WITH DDFPE SHOWS THAT PSP, IN COMPARISON TO TRUE PROGRESSION, ON MR IMAGING IS MORE PREVALENT AFTER CHEMORADIATION. THE HYPOTHESES TO BE TESTED IN THIS REVISED DIRECT TO PHASE II SBIR APPLICATION ARE AS FOLLOWS: 1) TREATMENT WITH DDFPE WILL ALTER EXPRESSION OF BIOMARKERS ASSOCIATED WITH TUMOR HYPOXIA AND 2) BLOOD-BASED BIOMARKERS WILL ENABLE DIFFERENTIATION OF PSP FROM PROGRESSIVE DISEASE (PD). THUS, OUR SPECIFIC AIMS ARE DIRECTED TO EXPLORE THIS PIVOTAL OBSERVATION WHICH IS TO CORRELATE BLOOD-BASED BIOMARKERS FOR HYPOXIA WITH RADIOSENSITIZER TREATMENT AND PSP. FYR DIAGNOSTICS WILL PARTNER WITH NUVOX TO ESTABLISH LIQUID BIOPSY ASSAYS THAT SUPPORT DDFPE THERAPEUTIC PRODUCT DEVELOPMENT. FYR WILL EMPLOY A MULTI-OMICS APPROACH TO DISCOVER NOVEL BIOMARKERS UTILIZING ENABLING TECHNOLOGY TO ENRICH EXTRACELLULAR VESICLE (EV) SUBPOPULATIONS IN PATIENT BLOOD PLASMA. CIRCULATING EV BIOMARKERS WILL AID IN IDENTIFICATION OF PATIENTS WHO MAY BENEFIT MOST FROM RADIOSENSITIZER TREATMENT AND FACILITATE MONITORING OF RESPONSE TO TREATMENT WITH OR WITHOUT A RADIOSENSITIZER. FYR AND NUVOX WILL WORK SYNERGISTICALLY TO DISCOVER AND VALIDATE HYPOXIA BIOMARKERS TO CREATE AN ACCOMPANYING COMPANION DIAGNOSTIC ASSAY TO AID IN SAFE AND EFFECTIVE USE OF DDFPE. PSP BIOMARKER DEVELOPMENT WILL HAVE MASSIVE IMPLICATIONS IN PATIENT MANAGEMENT IN THE PRESENCE OR ABSENCE OF RADIOSENSITIZER TREATMENT, ULTIMATELY NECESSITATING CREATION OF LDT OR IVD ASSAYS. THIS IS THE FIRST TIME THAT LIQUID BIOPSIES WILL BE STUDIED IN GBM IN ASSOCIATION WITH A RADIOSENSITIZER. WE EXPECT TO GARNER VALUABLE INSIGHTS INTO GENE EXPRESSION IN CHEMORADIATION TREATMENT, SIGNATURES TO DISTINGUISH PSP FROM PD, AND PREDICTIVE PATTERNS WITH RESPECT TO OS.

DODECAFLUOROPENTANE EMULSION (DDFPE), NANO2? AS CEREBROPROTECTANT IN ISCHEMIC STROKE - ABSTRACT / PROJECT SUMMARY STROKE AFFECTS MORE THAN 795,000 PATIENTS PER YEAR IN THE US AND KILLS APPROXIMATELY 40,000. LONG-TERM MEDICAL CARE EXPENSE FOR STROKE IN THE US, COSTS OVER $34B PER YEAR. LARGE VESSEL OCCLUSION (LVO) STROKE ACCOUNTS FOR ALMOST 40% OF ISCHEMIC STROKES BUT CAUSES 95% OF MORTALITY AND 62% OF LONG-TERM DEPENDENCE. MECHANICAL THROMBECTOMY (MT), OR A COMBINATION OF MT AND TPA, HAS EMERGED AS STANDARD OF CARE TREATMENT OF LVO STROKE. UP TO 60% OF THROMBECTOMY PATIENTS ARE FIRST EVALUATED AT SPOKE HOSPITALS AND TRANSFERRED TO HUB HOSPITALS FOR MT. `TIME IS BRAIN' FOLLOWING STROKE, THE SOONER THERAPY CAN BE INSTITUTED, THE GREATER THE LIKELIHOOD OF PRESERVING NEUROLOGICAL FUNCTION. A THERAPY THAT COULD BE RAPIDLY DEPLOYED IN ALL STROKE PATIENTS TO PRESERVE THE BRAIN COULD PROVIDE ENORMOUS POTENTIAL BENEFIT TO STROKE PATIENTS. NANO2TM (AKA DODECAFLUOROPENTANE EMULSION, DDFPE) SIGNIFICANTLY DECREASED STROKE VOLUME (SV), BY ABOUT 85%, AND IMPROVED NEUROLOGICAL ASSESSMENT SCORE (NAS) IN RABBITS WHEN ADMINISTERED IV UP TO 3 HOURS FOLLOWING STROKE AND ALSO IMPROVED SV AND NAS IN PERMANENT RAT MCAO. IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE IB/II CLINICAL TRIAL OF ACUTE ISCHEMIC STROKE, IN WHICH PATIENTS RECEIVE STANDARD REPERFUSION THERAPY, NANO2 WAS SAFE AT ALL DOSE LEVELS. THE HIGHER DOSES OF NANO2 CAUSED SIGNIFICANTLY BETTER MODIFIED RANKIN SCALE (MRS) AT 30 AND 90-DAYS POST STROKE. EARLY ADMINISTRATION OF NANO2 (<5 HOURS FROM ONSET) PRESENTED WITH SIGNIFICANTLY BETTER NIH STROKE SCALE (NIHSS) SCORES. NANO2 IS ACTIVE AT VERY LOW DOSES (E.G. 0.1 TO 0.17 ML OF 2% W/VOL EMULSION PER KG BODY WEIGHT) AND CLEARS VIA EXHALATION WITH A TERMINAL HALF-LIFE OF ABOUT 90 MINUTES IN HUMANS. NANO2 WAS PREVIOUSLY TESTED AS AN ULTRASOUND CONTRAST AGENT IN 2,230 PATIENTS AND WAS CONSIDERED SAFE AND APPROVABLE BY THE FDA AND EMEA. THE SPECIFIC AIMS ARE 1) TO MANUFACTURE DDFPE GMP FOR SPAN STUDIES AND TO SCALE-UP GMP MANUFACTURING, 2) TO TEST DRUG IN TMCAO MODELS IN LEAN, ADULT AND AGED WISTAR RATS AND 3) TO PERFORM STUDIES IN OBESE, DIABETIC ZUCKER RATS AND SPONTANEOUSLY HYPERTENSIVE RATS. EXPECTED OUTCOME: NANO2 WILL SHOW GREAT EFFICACY IN RODENT TMCAO MODELS ENABLING THIS DRUG TO BE CONSIDERED AS A CANDIDATE FOR ENTRY INTO CLINICAL TRIALS IN ISCHEMIC STROKE SPONSORED BY STROKENET.

NANO2 ENHANCES IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCERS.

SBIR PHASE II: A CLOUD-BASED SERVICE FOR AUDIO ACCESS TO NEWS AND BLOGS

HIGH ROSOLUTION, 15-MICRON THIN, PIXLLATED, BACK-ILLUMINATED SOI CMOS VERTX SENSOR

LARGE AREA, HIGH DYNAMIC RANGE, SOLD STATE PHOTOMULTIPLIER ARRAY FOR CHERENKOV CALORIMETRY

NEW AWARD, "OPTIMIZATION OF IMPACT IONIZATION IN COMPOSITE NANO-CRYSTAL PHOTOVOLTAIC DEVICES"

NANO2 AS A CEREBROPROTECTANT IN A TMCAO STROKE MODEL IN MICE - PROJECT SUMMARY/ABSTRACT STROKE AFFECTS MORE THAN 795,000 PATIENTS PER YEAR IN THE US, KILLS APPROXIMATELY 140,000 AND IS THE SINGLE LARGEST CAUSE OF EXPENSE FOR LONG-TERM MEDICAL CARE IN THE US. ABOUT 87% OF STROKES ARE ISCHEMIC, 40% OF WHICH ARE LARGE VESSEL OCCLUSIONS (LVO). ACUTE ISCHEMIC STROKE (AIS) CAN BE TREATED BY RESTORING BLOOD FLOW, E.G. BY USING THE CLOT- BUSTING DRUG T-PA FOR ELIGIBLE PATIENTS. RECENTLY, MECHANICAL THROMBECTOMY (MT) HAS EMERGED AS STANDARD OF CARE FOR LVO STROKE. AS MT IS A SPECIALIZED PROCEDURE, UP TO 60% OF THROMBECTOMY PATIENTS ARE FIRST EVALUATED AT SPOKE HOSPITALS AND THEN TRANSFERRED TO A HUB HOSPITAL FOR MT. THE DURATION OF TIME FOR PATIENT TRANSFER FROM THE SPOKE TO THE HUB IS VARIABLE AND MAY BE IN EXCESS OF SEVERAL HOURS. REPERFUSION WITH TPA ALSO TAKES TIME, USUALLY SEVERAL HOURS FOR ADEQUATE BLOOD FLOW TO BE OBTAINED. A SAFE DRUG WHICH MAINTAINED OXYGENATION WITHIN THE AT-RISK REGION IN AIS COULD PRESERVE THE TISSUE UNTIL REPERFUSION IS ATTAINED, THEREBY INCREASING THE UTILITY OF REPERFUSION THERAPY. NUVOX PHARMA IS DEVELOPING A NOVEL OXYGEN THERAPEUTIC, NANO2TM (2% W/VOL DODECAFLUOROPENTANE EMULSION). IN MULTIPLE ANIMAL STUDIES IN STROKE, NANO2 MAINTAINED THE TISSUE VIABILITY IN THE PENUMBRA AND REDUCED THE VOLUME OF INFARCT BY 85%. IN A PHASE IB/II TRIAL IN AIS PATIENTS, NANO2 WAS SAFE AT ALL DOSE LEVELS (0.05, 0.10 & 0.17 ML/KG) ADMINISTERED 3 TIMES 90 MINUTES APART AND WAS SHOWN TO BE EFFICACIOUS. THE HIGH DOSE COHORT HAD A SIGNIFICANT IMPROVEMENT COMPARED TO PLACEBO IN THE FUNCTIONAL END-POINT OF THE MODIFIED RANKIN SCALE AT 30 AND 90 DAYS (P = 0.01 AND P=0.03, RESPECTIVELY). NUVOX HAS AN ACTIVE IND FOR A PHASE II TRIAL CALLED THE PROVEN TRIAL (PHASE II TO RESTORE OXYGEN IN LVO PATIENTS EN ROUTE FOR MT USING NANO2). WE HYPOTHESIZE THAT EARLY ADMINISTRATION OF NANO2 TO AIS PATIENTS WILL MAINTAIN VIABILITY OF TISSUE IN THE PENUMBRA UNTIL REPERFUSION CAN BE ATTAINED. THE NINDS HAS DEVELOPED THE STROKE PRECLINICAL ASSESSMENT NETWORK (SPAN) PROGRAM TO FIND NEUROPROTECTIVE AGENTS TO BRING TO THE CLINIC. TO MAKE THE NANO2 PROGRAM COMPETITIVE WITH THESE NEUROPROTECTANTS IN AN APPLICATION TO NIH STROKENET IN THE FUTURE, NUVOX MUST ENSURE THE SCIENTIFIC RIGOR AND REPRODUCIBILITY OF OUR PRECLINICAL STUDIES MATCH THE STANDARD OF SPAN. OUR PRECLINICAL DATA IS PROMISING, BUT LACKS THE INCLUSION OF AGED ANIMALS, OTHER COMORBIDITIES FOR STROKE AND LONG-TERM FUNCTIONAL OUTCOME MEASUREMENTS. IN THIS PHASE I STTR GRANT APPLICATION, WE PROPOSE TO CONDUCT STUDIES OF NANO2 IN A TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION (TMCAO) MOUSE MODEL USING THE INTRALUMINAL FILAMENT TECHNIQUE. THE STUDY WILL BE CONDUCTED IN TWO PHASES, FIRST IN HEALTHY MICE TO ESTABLISH THE MODEL WITH LESS CONFOUNDING VARIABLES FOLLOWED BY A SECOND PHASE IN AGED MICE AND MICE WITH COMORBIDITIES. SUCCESSFUL COMPLETION OF THE AIMS OF THIS STUDY WILL FULFILL THE NIH’S REQUIREMENT FOR RIGOR AND REPRODUCIBILITY SO THAT NANO2 CAN BE CONSIDERED AS A CANDIDATE FOR CLINICAL TRIALS IN STROKENET AND OTHER ORGANIZATIONS SUPPORTED BY NIH.

HIGH RESOLUTION, 15-MICRON THIN, PIXELLATED, BACK-ILLUMINATED SOI CMOS VERTEX SENSOR

DODECAFLUOROPENTANE PREVENTS ISCHEMIA REPERFUSION INJURY IN CONTEMPORARY ACUTE MYOCARDIAL INFARCTION MANAGEMENT

LARGE AREA HIGH DYNAMIC RANGE SOLD STATE PHOTOMULTIPLIER ARRAY FOR CHERENKOV CALORIMETRY

SONOTHROMBOLYSIS OF VASCULAR CLOTS WITH TARGETED BUBBLES

SBIR-PHASE I NEW; DIGITAL SILICON PHOTOMULTIPLIER ARRAY READOUT INTEGRATED CIRCUITS; ADAM LEE

B7-H3-TARGETED CONTRAST AGENT FOR ULTRASONIC IMAGING OF BREAST CANCER

PANCREATIC DUCTAL ADENOCARCINOMA TARGETED ULTRASOUND CONTRAST AGENT DEVELOPMENT

BREATH AEROSOL CAPTURE BY ELECTRIC FIELD CONCENTRATION - PROJECT SUMMARY THIS PROPOSED PROJECT IS AIMED AT DEVELOPING A METHOD FOR CAPTURING AND CONCENTRATING EXHALED BREATH AEROSOLS BY ELECTROSTATICALLY CHARGING THEM AND COLLECTING THEM ON SUB-MM DIAMETER AREAS FOR OPTIMAL TRACE AEROSOL DETECTION SENSITIVITY BY INFRARED TUNABLE LASER SPECTROSCOPY (TLS). AN IMMEDIATE APPLICATION FOR THIS TECHNOLOGY IS DETECTION OF TRACE AMOUNTS OF THE MARIJUANA INTOXICATING AEROSOL INGREDIENT TETRAHYDROCANNABINOL (THC), BUT OTHER APPLICATIONS INCLUDE DETECTION OF DANGEROUS DRUGS AND VIRUSES. PRIOR WORK ON SPECTROSCOPIC SENSING OF THC AT VOX BIOMEDICAL INDICATED THAT EXHALED BREATH AEROSOL AREA CONCENTRATION IS NEEDED BECAUSE THE SUB-NG AMOUNTS OF THC IN EXHALED BREATH AEROSOLS ARE SO SMALL THAT THE CAPTURED AEROSOLS DO NOT ENTIRELY COVER THE 1 CM2 SAMPLE AREAS TYPICALLY USED IN INFRARED SPECTROSCOPY, THEREBY REDUCING SYSTEM SENSITIVITY. MODELING SHOWED THAT AEROSOL CONCENTRATION ONTO SUB-MM DIAMETER AREAS OF DIAMETER EQUAL TO THE DIFFRACTION-LIMITED FOCUSED TLS QUANTUM CASCADE LASER SPOT SIZE ENABLES OPTIMAL DETECTION SENSITIVITY, RESULTING IN SEVERAL ORDERS OF MAGNITUDE IMPROVED SPECTROSCOPIC DETECTION SENSITIVITY BECAUSE A MUCH LARGER FRACTION OF THE FOCUSED PROBE LASER LIGHT WILL BE ABSORBED BY THE CONCENTRATED ANALYTE. THE REQUIRED SUB-MM DIAMETER AREA THC AEROSOL ANALYTE CONCENTRATION WILL BE ACHIEVED BY ELECTROSTATICALLY CHARGING THE EXHALED BREATH THC AEROSOLS AND THEN ACCELERATING THE CHARGED AEROSOLS ONTO AN ELECTRICALLY CONDUCTING SILICON COUPON COVERED WITH A NON-CONDUCTING OXIDE LAYER INTO WHICH A 0.1 MM DIAMETER OPENING IS PHOTOLITHOGRAPHICALLY DEFINED. THIS PHOTOLITHOGRAPHIC WAFER FABRICATION PROCESS WILL BE CARRIED OUT IN A LOCAL SEMICONDUCTOR FOUNDRY. THE DESIGN OF THE PATTERNED SILICON WAFER WILL BE SUCH THAT THE WAFER CAN BE SECTIONED INTO IDENTICAL SMALL COUPONS, EACH WITH A SINGLE 0.1 MM DIAMETER OXIDE OPENING, THAT WILL THEN BE USED IN THE PLANNED ANALYTE DEPOSITION EXPERIMENTS. TO DEMONSTRATE THE EFFICACY OF THIS PROPOSED NEW AEROSOL CONCENTRATION METHOD DURING PHASE I VOX BIOMEDICAL WILL FIRST USE A WELL-CHARACTERIZED ALPHAZURINE-A DYE OBTAINED FROM A NEBULIZER AND PRECISION INJECTED INTO A POLYCARBONATE CYLINDER AND CHARGED BY AN ELECTRIC FIELD OF SEVERAL KV/CM AS CREATED BY A CYLINDRICALLY SYMMETRIC ARRANGEMENT OF THREE TUNGSTEN TIP CORONA NEEDLES. SINCE THE ALPHAZURINE-A DYE IS WELL CHARACTERIZED BY ITS KNOWN SPECTRAL ABSORPTION CHARACTERISTICS, IT WILL BE POSSIBLE TO DETERMINE THE MINIMUM DETECTIBLE AMOUNTS OF DEPOSITED DYE AEROSOLS. FOLLOWING THE PHASE I ALPHAZURINE-A DYE CONCENTRATION STUDY, A MORE REFINED FEASIBILITY DEMONSTRATION WILL BE CARRIED OUT USING THC AEROSOLS THAT WILL BE GENERATED BY NEBULIZING METHANOL WITH QUANTITATIVELY KNOWN THC CONCENTRATIONS OBTAINED FROM COMMERCIAL THC-IN-METHANOL SOLUTIONS. PHASE II WILL THEN INCLUDE HUMAN MARIJUANA USER EXHALED BREATH MEASUREMENTS. SUCCESSFUL DEVELOPMENT OF THE PROPOSED NEW ELECTROSTATIC AEROSOL CONCENTRATION METHOD WILL PROVIDE BOTH LAW ENFORCEMENT AND EMPLOYEE SCREENING PERSONNEL WITH A NON-INVASIVE MEANS FOR IDENTIFYING MARIJUANA AND DRUG USERS IN REAL TIME. IF SUCCESSFUL, THIS AEROSOL CAPTURE TECHNIQUE COULD ALSO BE APPLIED TO IDENTIFYING EXHALED BREATH VIRUS CONTENT.

RAPID: AN EXTREMELY FAST MONTE CARLO DOSE COMPUTING SOFTWARE FOR NUCLEAR MEDICINE

IMAGE-GUIDED AUTOMATED ULTRAFAST LASER DEVICE FOR LARYNGEAL SURGERY TO EXPAND TREATMENT OPTIONS AND IMPROVE PATIENT OUTCOMES - FEMTOVOX IS BUILDING AN IMAGE-GUIDED AUTOMATED ULTRAFAST LASER TECHNOLOGY FOR VOICE BOX (LARYNX) SURGERY. CURRENT SOLUTIONS USING SCALPELS OR TRADITIONAL LASERS AREN’T AUTOMATED (TAKE LONGER), CAUSE MORE DAMAGE (MORE COMPLICATIONS, LONGER WOUND HEALING), ARE IMPRECISE (REQUIRE REPEAT SURGERIES) AND CAN SET PATIENTS’ AIRWAYS ON FIRE (HIGHER LIABILITY). OUR SYSTEM PROVIDES REAL-TIME CROSS-SECTIONAL IMAGING USING OPTICAL COHERENCE TOMOGRAPHY (OCT). THIS ALLOWS SURGEONS TO SELECT THE EXACT EXCISION DEPTH AND AUTOMATE LASER SCANNING TO REMOVE THE DEFINED TISSUE VOLUME WITH HIGHER PRECISION. IN CONTRAST TO EXISTING SOLUTIONS, ULTRAFAST LASERS PRODUCE NO COLLATERAL DAMAGE (DUE TO THEIR EXTREMELY SHORT PICOSECOND OR FEMTOSECOND PULSE DURATIONS). OVERALL, OUR SOLUTION WILL BE BETTER: IMPROVED CLINICAL OUTCOMES, HIGHER EFFICIENCIES AND INCREASED THROUGHPUT. WITH INDUSTRY-LEADING EXPERIENCE COMMERCIALIZING AUTOMATED ULTRAFAST LASER OPHTHALMIC SURGICAL DEVICES (INTRALASE, LENSX, VIALASE), WE HAVE THE EXPERTISE, VENDOR RELATIONSHIPS AND PROFESSIONAL NETWORK TO COMMERCIALIZE THIS DEVICE. WE AIM TO TARGET THE $1.8B SPENT ANNUALLY (US) ON LARYNGEAL SURGERY. OUR TECHNOLOGY IS THE SUPERIOR SOLUTION FOR THE ~120,000 LARYNX SURGERIES PERFORMED ANNUALLY IN THE US. IN ADDITION TO THESE EXISTING CASES, THERE’S A LARGE AND COMPELLING OPPORTUNITY FOR THE ~400,000 ANNUAL LARYNX BENIGN LESION DIAGNOSES, WHICH ARE RARELY OPERATED ON (~5% OF DIAGNOSES) DUE TO COLLATERAL DAMAGE CONCERNS, WHICH LEAVES MANY PATIENTS (AND SURGEONS) WITH NO SOLUTIONS. IN THE LONG TERM, WE ENVISION A PLATFORM TECHNOLOGY FOR BROADER ENT DEPLOYMENT (RHINOLOGY, ORAL CAVITY, THROAT). WITH THE POTENTIAL TO GREATLY IMPROVE LARYNGEAL SURGICAL OUTCOMES, THIS TECHNOLOGY ALIGNS CLOSELY WITH THE NIH’S MISSION OF IMPROVING HEALTH-RELATED OUTCOMES. WE SEE THE LARYNX AS A WELL-SUITED BEACHHEAD FOR THE FIRST NON- OPHTHALMIC ULTRAFAST LASER APPLICATION FOR SEVERAL REASONS. FIRSTLY, LARYNGOLOGISTS OR COMPREHENSIVE ENTS OPERATING ON THE LARYNX ARE VERY FAMILIAR WITH LASERS; HOWEVER, CURRENT LASERS CAUSE TOO MUCH COLLATERAL DAMAGE, 25% OF EXISTING LASER SURGERIES REQUIRE RE-TREATMENT AND CONSERVATIVE SPEECH THERAPY HAS HIGH FAILURE RATES. SECONDLY, THE LARYNX HAS VERY SENSITIVE TISSUE FOR WHICH AUTOMATION AND HIGHER PRECISION CAN PRESERVE MORE TISSUE. LASTLY, LARYNX TISSUE IS QUITE THIN AND OPTICALLY TRANSMISSIBLE, IDEAL FOR OCT IMAGING. THE PROJECT HAS THREE SPECIFIC AIMS IN ITS PHASE I STAGE. THE FIRST AIM IS TO DEMONSTRATE THE SUPERIORITY OF ULTRAFAST LASERS IN MINIMIZING COLLATERAL DAMAGE IN LARYNGEAL TISSUE. THE SECOND AIM FOCUSES ON CHARACTERIZING ULTRAFAST LASER-BASED COAGULATION USING THE CHICK CHORIOALLANTOIC MEMBRANE (CAM) AS A PRECLINICAL IN VIVO MODEL. THE THIRD AND FINAL AIM IS TO DEMONSTRATE SUB-SURFACE EXCISIONS IN CADAVERIC LARYNGEAL TISSUE, A GROUNDBREAKING CAPABILITY THAT COULD REVOLUTIONIZE LARYNGEAL SURGERY AS MANY BENIGN LESIONS ARE SUB-EPITHELIAL. COMPLETION OF ALL THESE AIMS WILL DEFINE THE OPTIMAL INSTRUMENT DESIGN AND OPERATING PARAMETERS TO ADVANCE INTO PHASE II IN VIVO ANIMAL STUDIES.

MACHINE LEARNING BASED DIFFERENTIAL MOBILITY SPECTROMETRY LIBRARY DEVELOPMENT - PROJECT SUMMARY THE GOAL OF THE PROJECT PROPOSED IS TO DEVELOP A GAS CHROMATOGRAPHY AND DIFFERENTIAL MOBILITY SPECTROMETRY (GC/DMS) MOLECULAR IDENTIFICATION LIBRARY FOR VOLATILE ORGANIC COMPOUNDS (VOCS) USING A DEEP NEURAL NETWORK APPROACH. VOX BIOMEDICAL SCIENTISTS WILL TEST THE HYPOTHESIS THAT A NOVEL, MULTI-TASK NEURAL NETWORK ARCHITECTURE CAN PREDICT CHARACTERISTICS OF AN PREVIOUSLY UNSEEN ANALYTE FROM ITS GC/DMS SPECTRUM. VOX BIOMEDICAL IS IN THE PROCESS OF COMMERCIALIZING THE GC/DMS BASED MICROANALYZER INSTRUMENT, DEVELOPED AT DRAPER, FOR DETECTING THE PRESENCE OF PSYCHOACTIVE DRUGS AND DISEASE THROUGH EXHALED BREATH ANALYSIS. WHILE DRUG DETECTION CONSISTS OF MEASURING THE CONCENTRATIONS IN THE EXHALED BREATH OF COMPOUNDS WHOSE IDENTITY IS WELL KNOWN (SUCH AS PSYCHOACTIVE OPIOIDS AND CANNABINOIDS), EXHALED BREATH DISEASE DETECTION IS FOCUSED ON CHARACTERIZATION OF A PARTICULAR DISEASE’S EXHALED VOLATILE ORGANIC COMPOUND SIGNATURE. VOLATILE ORGANIC COMPOUNDS (VOCS) ARE BYPRODUCTS OF CELLULAR METABOLISM THAT TRAVEL FROM CELLS THROUGHOUT THE BODY TO THE LUNGS, WHERE THEY ARE EFFICIENTLY EXHALED IN THE BREATH. VOCS HAVE BECOME OF INTEREST AS BIOMARKERS OF METABOLIC DISEASES SUCH AS CANCER, KIDNEY DISEASE AND DIABETES. THE CURRENT GENERATION OF EXHALED BREATH VOC BASED DISEASE DETECTION METHODS RELY ON GAS CHROMATOGRAPHY AND MASS SPECTROMETRY (GC/MS), WHICH, WHILE HIGHLY SENSITIVE, IS A COMPLEX ANALYTICAL MODALITY THAT IS EXPENSIVE, SLOW, AND MUST BE OPERATED BY SKILLED PROFESSIONALS. THE MICROANALYZER INSTRUMENT’S INHERENT PORTABILITY, EASE OF USE, AND ABILITY TO OBTAIN RESULTS AT THE POINT-OF- MEASUREMENTS MAKE IT AN IDEAL INSTRUMENT FOR BREATH-BASED DISEASE DETECTION. HOWEVER, THE CURRENTLY A GC/DMS PEAK CAN ONLY BE IDENTIFIED THROUGH CHARACTERIZATION OF A CHEMICAL STANDARD OR BY PERFORMING CONFIRMATORY GC/MS ANALYSIS USING A SIMILAR SAMPLE. THIS MAKES BIOMARKER DISCOVERY A RESOURCE AND TIME INTENSIVE PROCESS. THE CREATION OF A VOC CHEMICAL IDENTITY LIBRARY, AS WOULD RESULT FROM SUCCESSFUL COMPLETION OF THE PROPOSED PROJECT, WILL ALLOW THE IDENTITY OF SAMPLES INTRODUCED TO THE MICROANALYZER INSTRUMENT TO BE PREDICTED WITHOUT THE NEED FOR CONFIRMATORY STANDARD CHARACTERIZATION OR GC/MS WORK. THIS WILL MAKE BIOMARKER DISCOVERY FOR DISEASE A LESS RESOURCE INTENSIVE PROCESS EXPEDITING THE DISCOVERY AND CONFIRMATION OF BIOMARKERS FOR EARLY-STAGE DISEASE DETECTION, ULTIMATELY SAVING LIVES.

TARGETED AND NON-TARGETED MICROBUBBLES FOR PEDIATRIC APPLICATIONS

USING TEXT MESSAGING FOR DEVELOPMENTAL SCREENING IN YOUNG CHILDREN

STTR PHASE I: A CLINICAL DECISION SUPPORT TOOL FOR BRAIN MAGNETIC RESONANCE IMAGING (MRI) IN CHILDREN

MACHINE LEARNING-BASED RADIATION TOXICITY MITIGATION IN PEDIATRIC BRAIN CANCER

RETINAL IMAGE ANALYSIS SOFTWARE FOR NEURODEGENERATIVE DISEASE RESEARCH

DEVELOPMENT OF NOVEL SENSITIZER TO IMPROVE RESPONSE OF HYPOXIC TUMORS TO RADIATIO

STTR-PHASE I NEW; LOW-COST NANOSTRUCTURED THERMOELECTRIC MATERIALS FOR EFFICIENT POWER GENERATION AT LOW TEMPERATURE; NGOC NGUYEN

ADDITIVE-MANUFACTURED SOLID-STATE LIGHTING OPTICS AND LUMINAIRE ASSEMBLIES

NEW SBIR PHASE I 2009: RAD-HARD SOI CMOS ACTIVE PIXEL SENSOR FOR CHARGED PARTICLE DETECTION; PI - GEORGE WILLIAMS

ADDITIVE MANUFACTURE OF LOW LOSS DIELECTRIC OPTICS

LAMP VALUE-ADDED PRODUCER GRANTS - COVID

RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS

ONBOARD DATA PROCESSING FOR FAST DETECTORS

PROGRAMMABLE, RECONFIGURABLE SILICON PHOTODIODE ARRAY MODULE

PICOSECOND RATE X-RAY PHOTON COUNTING DETECTOR

SBIR PHASE I: A CLOUD-BASED SERVICE FOR AUDIO ACCESS TO NEWS AND BLOGS

HIGH-COUNT-RATE, HIGH RESOLUTION SINGLE PHOTON DETECTOR

LARGE AREA, LOW DARK COUNT VIS-UV SOLID STATE PHOTOMULTIPLIERS

IFS FOR DARK MATTER CHARACTERIZATION

COMPRESSIVE 3D IMAGING SPECTROMETER

PRECISION NANOPARTICLES FOR HIGH PERFORMANCE DEVICES

DEVELOPMENT OF A SYRINGE/SONICATION DEVICE EMPLOYED TO ADMINISTER DDFPE IN THE PREHOSPITAL SETTING

ADDITIVE-MANUFACTURED SUPERCONDUCTOR PHASE SHIFTERS

OPTIMIZATION OF IMPACT IONIZATION IN COMPOSITE NANO-CRYSTAL PHOTOVOLTAIC DEVICES

INCREASING GRAPE DIVERSITY IN THE U.S. WINE INDUSTRY

COMMUNICATING RESEARCH TO PUBLIC AUDIENCES (CRPA) PROGRAM: COLLECTING, SHARING AND BUILDING FROM SUCCESSFUL PRACTICES

THE PROGRAM IS TO HELP UNDERSTAND THE BOTSWANA RAPIDLY EVOLVING DIGITAL AND SOCIAL MEDIA LANDSCAPE FOCUSING ON THE DETECTION AND ANALYSIS OF MISINFORMATION

PURPOSE: TO SUPPORT A CHORAL PERFORMANCE PROJECT.

THROUGH HANDS-ON EXPERIMENT-BASED COURSES, SCIENCE KITS, AND YOUTUBE VIDEOS THE PROJECT AIMS TO EMPOWER CHILDREN IN UNDERSERVED AREAS TO DEVELOP A PASSION FOR SCIENCE.

PURPOSE: TO SUPPORT A CHORAL COMMISSIONING AND PERFORMANCE PROJECT.

PURPOSE: TO SUPPORT A CHORAL CONCERT IN CELEBRATION OF AMERICAS 250TH ANNIVERSARY.

TO SUPPORT AN AUDIENCE ENGAGEMENT PROGRAM.

SEC. 9007 REAP-RENEW ENERGY SYS GRANTS (MAN)

"PROPAGANDAPOLIS" IS A DOCUMENTARY INITIATIVE OF THE VOXPOT GROUP THAT AIMS TO ILLUMINATE THE COMPLEX LANDSCAPE OF DISINFORMATION, PROPAGANDA, AND PSYCHOLOGICAL WARFARE IN CENTRAL AND EASTERN EUROPE.

PURPOSE: TO SUPPORT A TRAINING PROGRAM FOR DIRECTORS OF ARTISTIC SIGN LANGUAGE.

PURPOSE: TO SUPPORT A COMMISSIONING AND PERFORMANCE PROJECT FOCUSED ON ADDICTION RECOVERY.

PURPOSE:&NBSP;TO SUPPORT A CHORAL PERFORMANCE PROJECT.&NBSP;

PURPOSE: TO SUPPORT A CHORAL PERFORMANCE PROJECT CELEBRATING VOX FEMINAS 25TH ANNIVERSARY.

TO SUPPORT A COMMISSIONING AND PERFORMANCE PROJECT OF A NEW CHORAL WORK BY COMPOSER ANDREA RAMSEY.

THROUGH INNOVATIVE AFTER-SCHOOL COURSES THE PROJECT AIMS TO PROMOTE AFTER-SCHOOL MENTORSHIP CULTURE IN BULGARIAN SCHOOLS.

THROUGH HANDS-ON EXPERIMENT-BASED COURSES, SCIENCE KITS, AND YOUTUBE VIDEOS THE PROJECT AIMS TO EMPOWER CHILDREN IN RURAL AREAS TO DEVELOP A PASSION FOR SCIENCE.

THROUGH HANDS-ON EXPERIMENT-BASED COURSES, SCIENCE KITS, AND YOUTUBE VIDEOS THE PROJECT AIMS TO EMPOWER CHILDREN TO DEVELOP A PASSION FOR SCIENCE.

TO SUPPORT A PERFORMANCE PROJECT FEATURING MUSIC OF THE ITALIAN RENAISSANCE AND THE MUSIC OF THE 17TH AND 18TH CENTURIES.

TO SUPPORT BODYVOXS PERFORMANCE TOUR OF OREGON.

TO SUPPORT A PERFORMANCE TOUR TO UNDERSERVED COMMUNITIES IN ALASKA.

TO SUPPORT THE WORLD PREMIERE OF A NEW WORK CHOREOGRAPHED BY ARTISTIC DIRECTORS JAMEY HAMPTON AND ASHLEY ROLAND.

FUNDS COVERED PART OF THE HONORARIA FOR AMERICAN CONDUCTOR VALERY RYVKIN, ARTISTIC DIRECTOR OF THE OPERA SANTA BARBARA, WHO CONDUCTED A MASTERCLASS F

TO ORGANIZE THE WORKSHOPS CONDUCTED BY U.S. SPEAKER IN ECOTOURISM JIM BELLAMY IN COCHABAMBA. THE COST INCLUDES: ROOM RENTAL SOUND SYSTEM RENTAL C

HIGH COUNT RATE, PIXELATED APDS FOR DIRECT X-RAY DETECTION

REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT